ANTH
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2018 Q1 | -0.20 | $0 | -$9M |
| 2017 Q4 | -0.76 | $0 | -$6M |
| 2017 Q3 | -0.43 | $0 | -$6M |
| 2017 Q2 | 0.92 | $0 | -$10M |
| 2017 Q1 | -1.73 | $0 | -$14M |
| 2016 Q4 | -2.45 | $0 | -$12M |
| 2016 Q3 | -3.16 | $0 | -$15M |
| 2016 Q2 | -2.79 | $0 | -$12M |